Cytokine release syndrome is a complex inflammatory reaction that can occur when the immune system suddenly releases large amounts of specialized proteins called cytokines into the bloodstream, potentially affecting multiple organs throughout the body.

Understanding Cytokine Release Syndrome

Cytokine release syndrome, often shortened to CRS, happens when your body’s defense system goes into overdrive. Under normal circumstances, cytokines—small proteins that act as messengers between cells—help coordinate your immune response to threats. They control how your blood cells grow and how your immune cells behave. However, when too many cytokines flood into your bloodstream all at once, they can trigger widespread inflammation that may damage organs and tissues throughout your body.^[1]

This condition falls under the broader category of what doctors sometimes call a cytokine storm, a term that captures the overwhelming nature of the immune response. While cytokine release syndrome and cytokine storm share similar features, they have distinct characteristics. When CRS occurs as a result of medical treatment, symptoms might not appear immediately—they can be delayed for days or even weeks. In contrast, an immediate-onset reaction is typically considered a cytokine storm, though severe cases of CRS have also been described using this term.^[5]

Epidemiology

The frequency of cytokine release syndrome varies considerably depending on what triggers it and which specific treatments are involved. Among patients receiving CAR-T cell therapy—a type of cancer immunotherapy where a patient’s own immune cells are modified to fight cancer—CRS can occur in anywhere from 37% to 93% of cases, though the severity differs widely. Severe cases requiring intensive intervention occur in approximately 1% to 23% of patients, depending on the specific CAR-T product used.^[8]

The syndrome doesn’t affect all patient groups equally. People with certain types of blood cancers who haven’t received chemotherapy before their immunotherapy appear to be at higher risk for severe reactions. Patients with high levels of cancer cells in their body—what doctors call high tumor burden—also face greater likelihood of developing CRS. Additionally, the dose of CAR-T cells given can influence risk, with higher doses potentially leading to more frequent or severe cases.^[14]

Infections occurred in up to 23% of patients following CAR-T therapy and 24% after treatment with bispecific T-cell engagers (another type of immunotherapy), adding complexity to the clinical picture. These numbers highlight that cytokine release syndrome represents a significant consideration in modern cancer treatment, though most cases remain manageable with appropriate medical care.^[11]

Causes

Cytokine release syndrome develops when your immune system experiences a dramatic activation, causing large numbers of white blood cells to release their chemical messengers all at once. This massive release creates a cascading effect where cytokines trigger even more white blood cells to activate and produce additional cytokines, creating what scientists describe as a positive feedback loop of inflammation.^[5]

The most common trigger for CRS in medical settings is cancer immunotherapy, particularly treatments that harness the power of T-cells—specialized immune cells that can identify and destroy cancer cells. CAR-T cell therapy and bispecific antibodies represent the treatments most frequently associated with this syndrome. In these therapies, immune cells become highly activated as they engage with and attack cancer cells, releasing large quantities of inflammatory proteins in the process.^[1]

When scientists have analyzed blood samples from patients experiencing CRS after CAR-T therapy, they’ve found elevated levels of multiple cytokines, including IL-6, IFN-γ, IL-8, IL-10, and several others. Among these, IL-6 appears to play a central role in the syndrome’s development. Interestingly, many of these cytokines aren’t actually produced by the modified T-cells themselves, but rather by other immune cells called myeloid cells, which become activated through interactions with the T-cells.^[5]

Beyond immunotherapy, CRS can also result from bacterial and viral infections, where the immune system’s aggressive response to the pathogen triggers excessive cytokine release. Certain monoclonal antibody medications used to treat various conditions can also cause what’s sometimes called an infusion reaction, which represents another form of cytokine release syndrome.^[1][7]

Risk Factors

Several factors can increase a person’s likelihood of developing cytokine release syndrome, though predicting exactly who will experience it remains challenging. Patients with autoimmune diseases—conditions where the immune system mistakenly attacks the body’s own tissues—may face elevated risk. This makes sense given that their immune systems are already in a heightened state of activity.^[1]

Certain genetic conditions that affect immune system function also increase vulnerability to CRS. Hemophagocytic lymphohistiocytosis (HLH) represents one such condition, where the immune system becomes excessively activated and unable to shut down properly. People with HLH have a known predisposition to developing cytokine release syndrome.^[1]

For patients receiving immunotherapy, the amount of cancer in the body—the tumor burden—represents a significant risk factor. Those with large amounts of disease face higher chances of developing CRS, likely because the interaction between numerous cancer cells and activated immune cells generates more opportunities for massive cytokine release. Similarly, the dose of CAR-T cells administered can influence risk, with evidence suggesting that higher cell doses may correlate with increased CRS frequency or severity.^[14]

Patients with blood cancers who haven’t received prior chemotherapy appear particularly vulnerable to severe reactions during their first infusion of certain antibody treatments. These severe cases tend to have rapid onset and acute symptoms that require immediate medical attention.^[7]

Symptoms

The symptoms of cytokine release syndrome can range from mild to life-threatening, and they often begin subtly before potentially progressing to more serious manifestations. Many patients initially feel as though they have the flu, with general malaise and body aches that might not immediately raise alarm.^[1]

Fever represents one of the earliest and most common signs of CRS, often preceding other symptoms. This fever may fluctuate rather than remaining constant, and it typically appears within 24 hours to two weeks after receiving immunotherapy treatment. Along with fever, patients frequently experience chills, sometimes severe enough to cause shaking.^[12][14]

As cytokines circulate through the bloodstream, they can affect multiple body systems simultaneously. Neurological symptoms may include headaches, confusion, dizziness, and in some cases, difficulty coordinating movements. The digestive system may respond with nausea, vomiting, and diarrhea. Patients often report significant fatigue that goes beyond ordinary tiredness, accompanied by joint and muscle pain that can be quite uncomfortable.^[1]

Respiratory symptoms can develop as inflammation affects the lungs and airways. Patients may experience rapid, shallow breathing, difficulty catching their breath, or a sensation of not getting enough air. Some people notice difficulty swallowing or develop a scratchy throat that makes speaking uncomfortable.^[7][14]

Cardiovascular changes represent some of the more concerning manifestations of CRS. The heart may beat unusually fast—a condition called tachycardia—while blood pressure may drop, sometimes dangerously low in a state called hypotension. These changes reflect the widespread effects of inflammatory cytokines on blood vessels throughout the body. Some patients develop skin rashes as another visible sign of the immune system’s heightened activity.^[7]

In severe cases, the syndrome can progress to cause serious complications affecting major organs. The lungs may fail to provide adequate oxygen, requiring mechanical breathing support. The heart can become weakened, developing into cardiomyopathy or heart failure. Kidneys and liver may stop functioning properly, and blood vessels can become abnormally permeable in a condition called capillary leak syndrome, where fluid escapes from vessels into surrounding tissues.^[1]

Prevention

Preventing cytokine release syndrome entirely remains challenging given that it often results from necessary medical treatments for serious conditions like cancer. However, medical teams can take several approaches to reduce risk and catch the syndrome early when it does develop.

Close monitoring represents the first line of defense. Patients receiving treatments associated with CRS, particularly CAR-T cell therapy or bispecific antibodies, require careful observation for signs of the syndrome. Healthcare providers typically monitor vital signs—temperature, heart rate, blood pressure, and breathing rate—at regular intervals or continuously, depending on the patient’s risk level. The first sign usually involves fever, which serves as an important early warning signal.^[14]

Some medical centers have explored using medications preventively or at the earliest signs of trouble. Tocilizumab, a medication that blocks the IL-6 cytokine receptor, has been studied for prophylactic, preemptive, or risk-adapted use. Early evidence suggests that strategic use of this medication may reduce the risk of severe CRS without diminishing the cancer-fighting effectiveness of the immunotherapy. However, approaches to preventive medication use vary among treatment centers and continue to evolve as more data becomes available.^[14]

Patients with high tumor burden—meaning large amounts of cancer in their body—represent a group where doctors might consider strategies to reduce disease load before starting immunotherapy. Lower tumor burden may translate to less aggressive immune activation and potentially milder CRS if it occurs, though this approach must be carefully balanced against the urgency of treating the underlying cancer.^[14]

For patients with known risk factors such as autoimmune diseases or genetic conditions affecting immune function, extra vigilance becomes even more important. While these conditions don’t necessarily preclude immunotherapy, they signal the need for enhanced monitoring and perhaps lower thresholds for intervening with treatment.^[1]

Pathophysiology

The biological mechanisms underlying cytokine release syndrome involve complex interactions between multiple types of immune cells and the chemical messengers they produce. Understanding these processes helps explain why the syndrome develops and how treatments work to control it.

The cascade typically begins when large numbers of white blood cells become activated simultaneously. In the context of CAR-T therapy, modified T-cells recognize and bind to cancer cells, triggering the T-cells to release cytokines as part of their tumor-fighting response. These cytokines don’t just attack cancer—they also activate other immune cells in the vicinity, including B cells, natural killer cells, macrophages, dendritic cells, and monocytes.^[5]

This activation creates a self-amplifying cycle. When immune cells are activated through interactions between receptors on their surface and specific molecules called ligands, they respond by producing and releasing even more cytokines. These newly released cytokines then bind to receptors on other immune cells, stimulating those cells to activate and produce their own cytokines. This positive feedback loop explains how cytokine levels can rapidly escalate to dangerous concentrations.^[5]

Interestingly, research using laboratory experiments has revealed that many of the cytokines found in patients with CRS don’t actually come from the therapeutic T-cells themselves. Instead, cells from the myeloid lineage—including monocytes that transform into macrophages—serve as major producers of inflammatory cytokines like IL-6, MCP-1, and MIP-1. The T-cells appear to license these myeloid cells to produce cytokines through various activating interactions.^[5]

Among the numerous cytokines involved in CRS, interleukin-6 (IL-6) plays a particularly central role. Elevated IL-6 levels correlate with CRS severity, and blocking the IL-6 receptor with medications like tocilizumab has proven effective in treating the syndrome. Other important cytokines include interferon-gamma (IFN-γ), which helps coordinate immune responses; IL-8, which attracts more immune cells to inflamed areas; and IL-10, which normally helps regulate inflammation but becomes dysregulated in CRS.^[5]

The widespread inflammation triggered by excessive cytokines affects blood vessels throughout the body, making them more permeable and allowing fluid to leak into surrounding tissues. This increased permeability helps explain many CRS symptoms: fluid accumulation in lungs causes breathing difficulties, leakage in blood vessels leads to low blood pressure, and widespread tissue swelling can impair organ function. The heart must work harder to pump blood through this inflamed vascular system, potentially leading to cardiac strain or failure in severe cases.^[1]

Different organs show varying sensitivity to cytokine-induced damage. The kidneys, liver, and lungs appear particularly vulnerable, which explains why these organs often show signs of dysfunction or failure in severe CRS. The blood-brain barrier—normally a protective shield that prevents many substances from entering the brain—can also become compromised, allowing inflammatory mediators to affect the central nervous system and produce neurological symptoms.^[1]

Laboratory findings in CRS patients reflect this multi-system inflammation and dysfunction. Blood tests may show elevated C-reactive protein and other markers of inflammation, increased levels of various cytokines, abnormal counts of different blood cell types, and evidence of organ stress such as elevated liver enzymes or kidney function markers. D-dimer levels rise, indicating activation of the blood clotting system, while factor I deficiency can develop, potentially leading to excessive bleeding despite the concurrent clotting activation.^[5]

The timing of CRS development relates to the kinetics of immune cell activation and cytokine production. After CAR-T infusion, it typically takes time for the modified cells to encounter cancer cells, become fully activated, and trigger the cascade of events leading to widespread cytokine release. This explains why symptoms may not appear immediately but rather develop over hours to days, with peak cytokine levels and symptoms often occurring several days after treatment begins.^[12]